These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
140 related items for PubMed ID: 17210865
21. R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy. Halaas JL, Moskowitz CH, Horwitz S, Portlock C, Noy A, Straus D, O'Connor OA, Yahalom J, Zelenetz AD. Leuk Lymphoma; 2005 Apr; 46(4):541-7. PubMed ID: 16019482 [Abstract] [Full Text] [Related]
22. [Relationship between clinopathological features and outcome of rituximab treatment for diffuse large B-cell lymphoma]. Zhang HY, Guan ZZ, Wang B, Huang HQ, Xia ZJ, Lin TY. Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):381-4. PubMed ID: 18953841 [Abstract] [Full Text] [Related]
26. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations]. Luo DL, Liu YH, Zhang F, Xu FP, Yan LX, Chen J, Xu J, Luo XL, Zhuang HG. Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242 [Abstract] [Full Text] [Related]
28. TP53 and outcome in DLBCL: not only the coding region. Jardin F, Coiffier B. Blood; 2013 May 30; 121(22):4433-4. PubMed ID: 23723442 [Abstract] [Full Text] [Related]
29. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Micallef IN, Kahl BS, Maurer MJ, Dogan A, Ansell SM, Colgan JP, Geyer S, Inwards DJ, White WL, Habermann TM. Cancer; 2006 Dec 15; 107(12):2826-32. PubMed ID: 17099879 [Abstract] [Full Text] [Related]
31. Successful treatment of diffuse large B-cell lymphoma following Waldenström's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab. Uchino K, Sameshima H, Miyamoto T, Iino T, Kato K, Henzan H, Aoki K, Nagafuji K, Gondo H, Harada M. Intern Med; 2004 Feb 15; 43(2):131-4. PubMed ID: 15005256 [Abstract] [Full Text] [Related]
32. Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy. Walter E, Schmitt T, Dietrich S, Ho A, Witzens-Harig M. Leuk Lymphoma; 2012 Nov 15; 53(11):2290-2. PubMed ID: 22475324 [No Abstract] [Full Text] [Related]
33. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. Landsburg DJ, Falkiewicz MK, Petrich AM, Chu BA, Behdad A, Li S, Medeiros LJ, Cassaday RD, Reddy NM, Bast MA, Vose JM, Kruczek KR, Smith SE, Patel P, Hernandez-Ilizaliturri F, Karmali R, Rajguru S, Yang DT, Maly JJ, Blum KA, Zhao W, Vanslambrouck C, Nabhan C. Br J Haematol; 2016 Nov 15; 175(4):631-640. PubMed ID: 27469075 [Abstract] [Full Text] [Related]